Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where R. Jeffrey Lee is active.

Publication


Featured researches published by R. Jeffrey Lee.


International Journal of Radiation Oncology Biology Physics | 2003

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy.

David K. Gaffney; Derek Haslam; Alex Tsodikov; Elizabeth H. Hammond; James Seaman; Joseph A. Holden; R. Jeffrey Lee; Karen Zempolich; Mark K. Dodson

PURPOSE The purpose of this study was to examine a variety of biomarkers in carcinoma of the cervix to better characterize (1). the natural history of the disease, (2). response to radiotherapy (RT), and (3). potential for new therapeutic strategies. MATERIALS AND METHODS Fifty-five patients with Stage IB-IVA carcinoma of the cervix, treated with definitive intent RT, and on whom tumor tissue blocks were available were included in this study. Charts were reviewed for clinical parameters and disease status. Immunohistochemistry was performed for epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), CD34, topoisomerase II alpha (topo-II), and cyclooxygenase-2 (COX-2). Univariate and multivariate Cox proportional hazards modeling was performed with disease-free survival (DFS) and overall survival (OS) as the end points. Biomarkers were evaluated for correlation between various prognostic factors. RESULTS In this series of 55 patients with carcinoma of the cervix treated with definitive RT, only stage was significant on univariate analysis for DFS (p < 0.0001). On univariate analysis, increasing FIGO stage (p < 0.0001) and membranous staining of EGFR (p < 0.037) indicated diminished OS. On multivariate analysis for DFS, COX-2, VEGF, and stage were significant (p = 0.012, p = 0.014, and p = 0.03, respectively), with increased expression indicating a worse prognosis. For OS, multivariate analysis revealed that VEGF, EGFR, and FIGO stage were significant (p = 0.005, p = 0.011, and p < 0.0001, respectively). Significant direct correlations were identified between VEGF and CD34 (p = 0.04), COX-2 and topo-II (p = 0.04), COX-2 and grade (p = 0.04), and tumor size and clinical stage (p = 0.04). CONCLUSION Multivariate analysis revealed that increased staining for VEGF and COX-2 indicated diminished DFS, and VEGF and EGFR identified patients at increased risk of death. A significant direct correlation between VEGF and CD34 implicates the process of angiogenesis. Topo-II is a proliferative marker and it correlated directly with COX-2, indicating that expression of COX-2 may be greater in more proliferative tumors. Increased expression of EGFR, VEGF, and COX-2 has identified patients with a worse prognosis in cancer of the cervix. These data support the investigation of therapeutics that target these proteins in carcinoma of the cervix.


Urology | 1994

Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy: fifteen-year results.

R. Jeffrey Lee; William T. Sause

OBJECTIVE To assess the long-term outcome of patients with lymphadenectomy-staged prostate cancer treated with external beam radiotherapy. METHODS A retrospective analysis was performed on all patients with prostate cancer who underwent staging pelvic lymphadenectomy before treatment with definitive radiotherapy from 1970 to February 1978. This included 71 patients who were evaluated for a minimum of fifteen years. No patients were lost to follow-up. Thirty-five patients were node negative and 36 were node positive. RESULTS Fifteen-year actuarial overall survival, cause-specific survival, and local control for the 20 patients with clinically organ-confined disease (T1b-T2 N0M0) was 40 percent, 75 percent, and 92 percent, respectively. The results for the 15 T3 N0M0 patients were 15 percent, 22 percent, and 60 percent. Patients with positive nodes did much worse, with rates of 5 percent, 6 percent, and 45 percent. Thirty-four patients received hormonal therapy at the time of first failure. No patient who was clinically free of disease at fifteen years had an elevated level of prostate-specific antigen (PSA). CONCLUSIONS Our data suggest excellent results in a cohort of patients (T1b-T2 N0M0) treated with primary radiotherapy who would be considered candidates for radical prostatectomy. Outcome is significantly worse in patients with T3 lesions and node-positive disease.


Gynecologic Oncology | 2005

Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.

Christopher M. Lee; Dennis C. Shrieve; Karen Zempolich; R. Jeffrey Lee; Elizabeth H. Hammond; Diana L. Handrahan; David K. Gaffney


International Journal of Radiation Oncology Biology Physics | 2007

Intensity-Modulated Radiotherapy Using Implanted Fiducial Markers With Daily Portal Imaging: Assessment of Prostate Organ Motion

Jergin Chen; R. Jeffrey Lee; Diana Handrahan; William T. Sause


Gynecologic Oncology | 2004

Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis

Christopher M. Lee; R. Jeffrey Lee; Elizabeth H. Hammond; Alex Tsodikov; Mark K. Dodson; Karen Zempolich; David K. Gaffney


International Journal of Radiation Oncology Biology Physics | 2004

Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy

John K O'Connor; James M. Avent; R. Jeffrey Lee; Jennifer Fischbach; David K. Gaffney


Urology | 2007

Activated STAT3 as a Correlate of Distant Metastasis in Prostate Cancer: A Secondary Analysis of Radiation Therapy Oncology Group 86-10

Javier F. Torres-Roca; Michelle DeSilvio; Linda B. Mora; Li Yan Khor; Elizabeth H. Hammond; Nazeel Ahmad; Richard Jove; Jeffrey D. Forman; R. Jeffrey Lee; Howard M. Sandler; Alan Pollack


International Journal of Radiation Oncology Biology Physics | 2004

DOES RADIOTHERAPY AROUND THE TIME OF PREGNANCY FOR HODGKIN'S DISEASE MODIFY THE RISK OF BREAST CANCER?

Jergin Chen; R. Jeffrey Lee; Alex Tsodikov; Lynn M. Smith; David K. Gaffney


International Journal of Radiation Oncology Biology Physics | 2006

Topoisomerase IIα expression correlates with diminished disease-free survival in invasive breast cancer

John K. O’Connor; Lisa J. Hazard; James M. Avent; R. Jeffrey Lee; Jennifer Fischbach; David K. Gaffney


Urology | 2007

Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.

O. Kenneth Macdonald; R. Jeffrey Lee; Greg Snow; Christopher M. Lee; Anthony W. Middleton; George W. Middleton; William T. Sause

Collaboration


Dive into the R. Jeffrey Lee's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

William T. Sause

Intermountain Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Elizabeth H. Hammond

Intermountain Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Howard M. Sandler

Cedars-Sinai Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge